SecBot SecBot

MVP Act

H.R. 7871 Rep. Brett Guthrie (R-KY-2) In committee
Bill text PDF
  1. Introduced Mar 9
  2. Committee Mar 9
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Mar 9, 2026Next: House vote
233d ago Mar 9, 2026: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 2 filings
Subscribe to see spend
Member trades
0trades in the last 90 days
None in these companies
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Biotech & Pharma 1
Search all 1 companies, their asks and price moves Subscribe

Summary

Medicaid VBPs for Patients Act or the MVP Act

Full summary3 paragraphs

This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. (Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.)

The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes.

Additionally, the bill (1) exempts sales of drugs that are made under value-based purchasing arrangements from calculations of the manufacturer average sales price for purposes of payments under Medicare medical services, if the manufacturer reports multiple best prices under Medicaid in accordance with the bill's changes; and (2) requires the Centers for Medicare & Medicaid Services to issue guidance on how state Medicaid programs may cover drugs in inpatient settings via value-based purchasing arrangements.

Library of Congress summary, Mar 9, 2026

Summary versions
  • Introduced in HouseMar 9, 2026

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.